Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05621369 · ClinicalTrials.gov registry record
Psorcast Mobile Study
A clinical trial of Psoriasis and Psoriatic Arthritis, sponsored by Sage Bionetworks.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05621369: Recruiting study of Psoriasis and Psoriatic Arthritis, sponsored by Sage Bionetworks.
NCT05621369 is a study of Psoriasis and Psoriatic Arthritis that is actively recruiting participants, run by Sage Bionetworks. The registered enrollment target is 1,000 participants, above the 481-participant average among 125 other Psoriasis trials with a reported enrollment target (108% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05621369, a study of Psoriasis and Psoriatic Arthritis, is actively recruiting participants, sponsored by Sage Bionetworks.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.
Primary Outcome
Results of participant self-assessment surveys will be analyzed using descriptive statistics. These results may also be compared with other intervention results.
Conditions Studied
Interventions
- BEHAVIORAL Participant self-assessment surveys
- BEHAVIORAL Psoriasis Draw
- BEHAVIORAL Psoriasis Area Photo
- BEHAVIORAL Finger and Toe Photos
- BEHAVIORAL Digital Jar Open
Study Locations (1)
Washington
- Sage Bionetworks - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2027-01-31 |
What NCT05621369 shows while recruiting
NCT05621369 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 481-participant average among 125 other Psoriasis trials with a reported enrollment target (108% higher).
The record links to 9 conditions, with Psoriasis appearing as the primary indexed condition, and to 5 interventions - of which Participant self-assessment surveys is the first listed.
NCT05621369 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05621369 about?
NCT05621369 is a clinical study titled "Psorcast Mobile Study". The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.
What is the current status of trial NCT05621369?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2022-01-01. Estimated completion is 2027-01-31.
What conditions does trial NCT05621369 study?
This clinical trial studies the following conditions: Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Joint Pain, Rheumatologic Disease.
What interventions are being tested in trial NCT05621369?
The interventions under investigation include: Participant self-assessment surveys (BEHAVIORAL), Psoriasis Draw (BEHAVIORAL), Psoriasis Area Photo (BEHAVIORAL), Finger and Toe Photos (BEHAVIORAL), Digital Jar Open (BEHAVIORAL).
Who is sponsoring clinical trial NCT05621369?
This trial is sponsored by Sage Bionetworks, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05621369 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05621369's enrollment target sits among peer trials
1,000 10th of 125 higher than 116 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI